A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: attuned (1), familiar (57), accustomed (7)

Bevacizumab (15mgkg), Carboplatin and Gemcitabine (1,8)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15)-CARBOPLATIN (AUC4)-GEMCITABINE (day 1, 8) Regimen • Ovary-Bevacizumab (15)-Carboplatin (AUC4)-Gemcitabine (1, 8
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab15mgkgCarboplatinAUC4Gemcitabineday18.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometrial carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Carfilzomib-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib-Dexamethasone (20) Regimen • Myeloma – Carfilzomib-Dexamethasone (20) Indi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib-dexamethasone20-ver1.pdf

Carfilzomib(14 day)-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib (14 day)-Dexamethasone (20) Regimen  Myeloma – Carfilzomib-Dexamethasone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib14-day-dexamethasone20-ver1.pdf

Going home with a CADD pump - patient information

Description
This factsheet explains what to expect if you are going home with a CADD pump.
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Going-home-with-a-CADD-pump-3090-PIL.pdf

Annual complaints report 2020-21

Description
ANNUAL COMPLAINTS REPORT 2020/21 RETROSPECTIVE PERFORMANCE LOOKING FORWARDS “All patients, from every background and walk of life, will experien
Url
/Media/UHS-website-2019/Patientinformation/Contactingus/Annual-complaints-report-2020-21.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Pembrolizumab2mg/kg

Description
Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option for treating
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Atezolizumab1680mg

Description
Chemotherapy Protocol LUNG CANCER Atezolizumab (1680mg 28 days) Regimen • Lung – Atezolizumab Indication • Atezolizumab is in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab1680mg.pdf
231 to 240 of 315
Previous … 22 23 24 25 26 … Next